DOMPERIDONE VS METOCLOPRAMIDE: COMPARATIVE EVALUATION OF EFFICACY IN TREATING DIABETIC GASTROPARESIS

A NAWAZ; S SHAH; A AHMED; M ULLAH

doi:10.54112/bcsrj.v2024i1.836

Authors

A NAWAZ Department of Gastroenterology DHQ Hospital Nowshera, Khyber Pakhtunkhwa, Pakistan
S SHAH Department of Gastroenterologist, King Abdullah Teaching Hospital Manshera, Pakistan
A AHMED Department of Medicine, Allama Iqbal Medical College Lahore Jinnah Hospital Lahore, Pakistan
M ULLAH Department of Medical D Unit LRH Peshawar, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.836

Keywords:

Diabetes Mellitus, Type 2, Gastroparesis, Domperidone, Metoclopramide, Comparative Study

Abstract

Diabetic gastroparesis, a common complication of diabetes mellitus, presents a challenging clinical scenario characterised by delayed gastric emptying and symptoms such as nausea, vomiting, abdominal pain, and bloating. Objectives: The primary aim of the study is to compare domperidone vs metoclopramide to evaluate their efficacy in treating diabetic gastroparesis. Methods: This comparative study was conducted in DHQ Hospital Nowshera Khyber Pakhtunkhwa—from June 2022 to June 2023. Data was collected from 190 patients from both genders. Patients meeting the inclusion criteria are randomised into Group A (Domperidone) and Group B (Metoclopramide). The severity of gastroparesis symptoms is assessed using validated symptom-scoring tools before treatment initiation and at regular intervals throughout the study. Results: Data was collected from 190 patients suffering from DM. The mean age of the patients in group A was 52.4 ± 8.2 years and in group B, 53.1 ± 7.5 years. There were 105 female and 185 male patients. The mean duration of DM is 12.3 ± 4.1 years and 11.8 ± 3.8 years in groups A and B, respectively. Group A (Domperidone) and Group B (Metoclopramide) demonstrated significant improvement in symptom scores from baseline to the final assessment. Group A exhibited a substantial reduction in symptom score from 18.2 ± 4.5 at baseline to 8.7 ± 3.2 at the end of the study (p < 0.001), while Group B showed a decrease from 17.9 ± 4.3 to 9.5 ± 3.8 (p < 0.001). Moreover, both groups experienced notable reductions in gastric emptying time. Conclusion: It is concluded that both domperidone and metoclopramide are effective in managing diabetic gastroparesis, with nuances in their safety profiles.

Downloads

Download data is not yet available.

References

Ingrosso MR, Camilleri M, Tack J, Ianiro G, Black CJ, Ford AC. Efficacy and safety of drugs for gastroparesis: systematic review and network meta-analysis. Gastroenterology. 2023;164(4):642-54.

Junqueira DR, Bennett D, Huh SY, Fahrbach K, Neupane B, Betts M. Risk of adverse events associated with domperidone and metoclopramide in gastroparesis: systematic review and meta-analysis. Drugs in R&D. 2023;23(1):1-20.

Sanger GJ, Andrews PL. An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis. Alimentary Pharmacology & Therapeutics. 2023;57(9):962-78.

Navas CM, Wadas ED, Zbib NH, Crowell MD, Lacy BE. Gastroparesis and severity of delayed gastric emptying: comparison of patient characteristics, treatments and medication adverse events. Digestive Diseases and Sciences. 2021;66:526-34.

Kalas MA, Trivedi B, Kalas M, Chavez LO, McCallum RW. Metoclopramide in Gastroparesis: Its Mechanism of Action and Safety Profile. Gastrointestinal Disorders. 2023;5(3):317-28.

Sarosiek I, Van Natta M, Parkman HP, Abell T, Koch KL, Kuo B, et al. Effect of domperidone therapy on gastroparesis symptoms: Results of a dynamic cohort study by NIDDK gastroparesis Consortium. Clinical Gastroenterology and Hepatology. 2022;20(3):e452-e64.

Yao J, Peng B, Gong X, Shi X, Fan S, Chen Q. Efficacy and Safety of Mecobalamin Combined with Prokinetic Agents in the Treatment of Diabetic Gastroparesis: A Meta-Analysis. Iranian Journal of Public Health. 2021;50(11):2161.

Naing LY, Heckroth M, Mathur P, Abell TL. Gastroparesis syndromes: emerging drug targets and potential therapeutic opportunities. Expert Opinion on Investigational Drugs. 2023;32(3):245-62.

Woods K, Gajendran M, Gonzalez Z, Bustamante-Bernal M, Sarosiek I, Espino K, et al. Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms. Journal of Investigative Medicine. 2022;70(5):1225-32.

Zheng T, Camilleri M. Management of gastroparesis. Gastroenterology & Hepatology. 2021;17(11):515.

McCallum RW, Parkman HP, Fass R, Bhandari BR, Carlson MR, Buck RD. Metoclopramide Nasal Spray in Women with Symptomatic Diabetic Gastroparesis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Clinical Gastroenterology and Hepatology. 2023.

Kant R, Pratti M, Khapre M, Yadav P, Dhingra V. Efficacy of prokinetic agents in diabetic gastroparesis comparing symptomatology and scintigraphy–An open-label trial. Caspian Journal of Internal Medicine. 2023;14(4):618.

Bonetto S, Gruden G, Beccuti G, Ferro A, Saracco GM, Pellicano R. Management of dyspepsia and gastroparesis in patients with diabetes. a clinical point of view in the year 2021. Journal of Clinical Medicine. 2021;10(6):1313.

Gajendran M, Sarosiek I, McCallum R. Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. Expert Review of Endocrinology & Metabolism. 2021;16(2):25-35.

Permana MD, Renaldi K. Management of Gastric Motility Disorder. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2020;19(1):25-36.

Petri M, Singh I, Baker C, Underkofler C, Rasouli N. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. Journal of Diabetes and its Complications. 2021;35(2):107733.

Cangemi DJ, Lacy BE. Gastroparesis: Myths, Misconceptions, and Management. Clinical and Experimental Gastroenterology. 2023:65-78.

Mora MCF, Matute CAM, Alemán R, Castillo M, Giambartolomei G, Schneider A, et al. Medical and surgical management of gastroparesis: a systematic review. Surgery for Obesity and Related Diseases. 2021;17(4):799-814.

Camilleri M. Beyond metoclopramide for gastroparesis. Clinical Gastroenterology and Hepatology. 2022;20(1):19-24.

Quratulain SA, Muhammad HA, Javed W, Farooq O. Effectiveness, Safety, and Tolerability of Esomeprazole and Domperidone in Gastroesophageal Reflux Disease. Pakistan Journal of Medical & Health Sciences. 2022;16(08):781-.